-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: George Goodno
George is the Director of State Policy Communications at BIO and enjoys the opportunity to advocate for and educate audiences about the positive societal and economic impact of the bioscience industry. Another great aspect of his job is getting to work with BIO’s broad network of state bioscience associations to help advance legislative and regulatory initiatives that will continue to improve this high-skill, high-wage industry. In his spare time, he enjoys running, skiing, hiking, gardening, and most of all, spending time with his awesome wife and two daughters.
Follow him on Twitter @ggoodno
Latest Posts
Biotech Remains Strong in Florida
Florida has always attracted visionaries – from Walt Disney to Kennedy Space Center. The ambition of great men helped transform inhospitable swamps into engines of the economy. However, with no income tax, and a large retiree population, Florida’s revenue long depended on booming tourism and the sales tax revenue it brought in. In the 1990’s, Florida’s leaders began to change that. Enterprise Florida was born. This public/private partnership was designed to identify and provide incentives Read More >
State Biotech Advocates Share Best Practices
Last week the Council of State Bioscience Associations (CSBA) held its annual retreat in Austin, TX, where 42 different state-based bioscience advocacy organization gathered to discuss legislative and regulatory best practices that support bioscience industry development. More than 90 invited participants engaged in discussions covering the topics of economic development initiatives, upcoming federal and state legislative industry priorities, and advocacy campaigns in the digital era. BIO’s State Government Relations team would like to once again Read More >
BioFlorida Conference: Here’s What You Missed
As I mentioned last week, BIO President & CEO James C. Greenwood kicked-off this week’s BioFlorida 14th Annual Conference with a keynote speech. Thanks to @BioFlorida2011 for tweeting some of his speech highlights. If you were not able to make it to Tampa for the conference, fear not, I’ve got you covered. Here’s a rundown of some of the things you missed: It’s All About Efficiency, Innovation and Globalization Goldman Sachs equity analyst Isaac Ro Read More >
BioFlorida’s Conference to Focus on Latest Technologies, Access to Capital
BIO President & CEO James C. Greenwood will commence next week’s BioFlorida 14th Annual Conference with a keynote speech at 8AM on Monday October 24, 2011 in Tampa, FL. Living up to its reputation as the premier business development, investing and networking event for Florida’s bioscience industry, more than 500 business, science and technology leaders are expected to attend the three-day conference, which runs Oct. 23-25 at the Marriot Waterside Hotel & Marina. This year’s Read More >
CHI Offering Free Webinar on FDA Draft Guidances
The California Healthcare Institute will be hosting a free online discussion on Tuesday, October 25, 2011 that addresses the FDA’s recently released draft guidance documents: Draft Guidance for Industry and Food and Drug Administration Staff – Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Review (Aug. 15, 2011) Draft Guidance for Industry, Clinical Investigators, and Food and Drug Administration Staff – Design Considerations for Pivotal Clinical Investigations for Medical Devices (Aug. 15, 2011) Date: October Read More >
